Gene Symbol: KRT20
Description: keratin 20
Alias: CD20, CK-20, CK20, K20, KRT21, keratin, type I cytoskeletal 20, cytokeratin 20, keratin 20, type I, protein IT
Species: human

Top Publications

  1. ncbi Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic, Rochester 55905, USA
    Cancer Chemother Pharmacol 48:S91-5. 2001
  2. ncbi [Distribution and force spectroscopy of CD20 antigen-antibody binding on the B cell surface]
    Qiulan Wang
    Department of Chemistry, Jinan University, Guangzhou 510632, China
    Sheng Wu Gong Cheng Xue Bao 27:131-6. 2011
  3. pmc Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis
    Yasunari Kawabata
    Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89 1 Enyacho, Izumo, Shimane 693 8501, Japan
    Diagn Pathol 5:75. 2010
  4. doi Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas
    Reyhan Bayrak
    Department of Pathology, School of Medicine, Fatih University, 06540 Emek, Ankara, Turkey
    Pathol Res Pract 207:156-60. 2011
  5. doi CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma
    Reda S Saad
    Department of Pathology, Sunnybrook Health Science Center, University of Toronto, Toronto, Ontario, Canada
    Appl Immunohistochem Mol Morphol 17:196-201. 2009
  6. ncbi The involvement of matrix metalloproteinases and inflammation in lumbar disc herniation
    Y Matsui
    Department of Orthopedic Surgery, Toyohashi Municipal Hospital, Aichi, Japan
    Spine (Phila Pa 1976) 23:863-8; discussion 868-9. 1998
  7. ncbi Granulomatous slack skin in childhood
    F M Camacho
    Department of Medical-Surgical Dermatology, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Spain
    Pediatr Dermatol 14:204-8. 1997
  8. ncbi Immunological effects following administration of interferon-alpha in patients with chronic hepatitis C virus (cHCV) infection
    E Jirillo
    Faculty of Medicine, University of Bari, Italy
    Immunopharmacol Immunotoxicol 18:355-74. 1996
  9. ncbi Brenner tumor of the ovary: a comparative immunohistochemical and ultrastructural study with transitional cell carcinoma of the bladder
    N G Ordonez
    University of Texas M D Anderson Cancer Center, Houston, USA
    Ultrastruct Pathol 24:157-67. 2000
  10. ncbi Distinguishing B and T lymphocytes by scanning electron microscopy
    J A Terzakis
    Kalvin Electron Microscope Laboratory, Department of Pathology, Lenox Hill Hospital, New York, NY 10021, USA
    Ultrastruct Pathol 24:205-9. 2000

Research Grants

  1. BRENDA MARIE SANDMAIER; Fiscal Year: 2016
  2. Sherie L Morrison; Fiscal Year: 2015
  3. Targeted therapy of pancreatic cancer with in vivo radionuclide generator
    Ekaterina Dadachova; Fiscal Year: 2012
  4. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2010
  5. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2009
  6. John M Timmerman; Fiscal Year: 2014
  7. Oliver W Press; Fiscal Year: 2015
  8. Edward A Neuwelt; Fiscal Year: 2016
  9. Oliver W Press; Fiscal Year: 2016
  10. Identification of biomarkers of fatty acid intake
    Hannia Campos; Fiscal Year: 2002

Detail Information

Publications530 found, 100 shown here

  1. ncbi Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic, Rochester 55905, USA
    Cancer Chemother Pharmacol 48:S91-5. 2001
    Clinical trials of an yttrium-90 (90Y)-conjugated monoclonal antibody to CD20 in patients with relapsed B cell non-Hodgkin lymphoma (NHL) are reviewed...
  2. ncbi [Distribution and force spectroscopy of CD20 antigen-antibody binding on the B cell surface]
    Qiulan Wang
    Department of Chemistry, Jinan University, Guangzhou 510632, China
    Sheng Wu Gong Cheng Xue Bao 27:131-6. 2011
    The lower expression of CD20 antigen molecules on the B cell membrane is the primary characteristic of B-chronic lymphocytic leukemia (B-CLL)...
  3. pmc Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis
    Yasunari Kawabata
    Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89 1 Enyacho, Izumo, Shimane 693 8501, Japan
    Diagn Pathol 5:75. 2010
    ..We assessed the expression of cytokeratin (CK) and apomucin (MUC) in ampullary carcinoma (AC) to develop a system for the classification of ACs on the basis of their clinical significance...
  4. doi Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas
    Reyhan Bayrak
    Department of Pathology, School of Medicine, Fatih University, 06540 Emek, Ankara, Turkey
    Pathol Res Pract 207:156-60. 2011
    Cytokeratin 7 (CK7) and cytokeratin 20 (CK20) are low molecular weight cytokeratins. The expressions of CK7 and CK20 have been studied in various primary and metastatic carcinomas...
  5. doi CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma
    Reda S Saad
    Department of Pathology, Sunnybrook Health Science Center, University of Toronto, Toronto, Ontario, Canada
    Appl Immunohistochem Mol Morphol 17:196-201. 2009
    There are limited data regarding CDX2 expression in rectal carcinoma. The CK20/CK7 immunoprofile of colorectal adenocarcinoma has been described in studies, which have mostly lumped colonic and rectal tumors together...
  6. ncbi The involvement of matrix metalloproteinases and inflammation in lumbar disc herniation
    Y Matsui
    Department of Orthopedic Surgery, Toyohashi Municipal Hospital, Aichi, Japan
    Spine (Phila Pa 1976) 23:863-8; discussion 868-9. 1998
    ..discs were stained with hematoxylin-eosin or toluidine blue or were immunostained with monoclonal antibodies to CD20, CD45RO, and CD68, anti-MMP-1, and anti-MMP-3, using the avidin-biotin-peroxidase complex method...
  7. ncbi Granulomatous slack skin in childhood
    F M Camacho
    Department of Medical-Surgical Dermatology, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Spain
    Pediatr Dermatol 14:204-8. 1997
    ..The lymphoid cells showed the following immunophenotype: CD43+ (MT1), CD45+, CD45RO+, CD20-. The phenotype of the giant cells was lysozyme positive, CD68+ and Mac387-...
  8. ncbi Immunological effects following administration of interferon-alpha in patients with chronic hepatitis C virus (cHCV) infection
    E Jirillo
    Faculty of Medicine, University of Bari, Italy
    Immunopharmacol Immunotoxicol 18:355-74. 1996
    ..patients IFN-alpha administration gave rise to an increase (above normality) of CD3+, CD4+, CD8+, CD14+, CD16+ and CD20+ cell absolute numbers, while in one patient the same markers dramatically dropped below normal range...
  9. ncbi Brenner tumor of the ovary: a comparative immunohistochemical and ultrastructural study with transitional cell carcinoma of the bladder
    N G Ordonez
    University of Texas M D Anderson Cancer Center, Houston, USA
    Ultrastruct Pathol 24:157-67. 2000
    ..benign BTs was evaluated together with that of 12 TCCs of the bladder using antibodies to thrombomodulin (TM), cytokeratin 20, cytokeratin 7, and carcinoembryonic antigen (CEA), all of which have been shown to react with TCCs of ..
  10. ncbi Distinguishing B and T lymphocytes by scanning electron microscopy
    J A Terzakis
    Kalvin Electron Microscope Laboratory, Department of Pathology, Lenox Hill Hospital, New York, NY 10021, USA
    Ultrastruct Pathol 24:205-9. 2000
    ..of T lymphocytes and B lymphocytes was verified by immunocytochemical staining respectively with CD3 and CD20 antisera...
  11. ncbi Expression of adhesion molecules in the host response to colon carcinoma
    B F Banner
    Department of Pathology, University of Massachusetts Medical Center, Worcester 01655, USA
    Ultrastruct Pathol 19:113-8. 1995
    ..samples were stained by a labeled avidin-biotin technique using primary antibodies to LFA-1 (CD11a), CD2, CD4, CD8, CD20, CD68, HLA-DR, ICAM-1 (CD54), and VCAM-1...
  12. ncbi Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response
    S Barni
    Divisione di Radioterapia Oncologica, Ospedale San Gerardo, Monza, Milano, Italy
    Tumori 77:227-31. 1991
    ..Moreover, in 8/16 patients, B lymphocytes (CD20), T suppressor cells (CD8+/CD57+), T cytotoxic cells (CD8+/CD57-), NK (CD16) and IL-2 receptor-expressing cells (..
  13. ncbi Lung adenocarcinomas metastatic to the brain with and without ultrastructural evidence of rootlets: an electron microscopic and immunohistochemical study using cytokeratins 7 and 20 and villin
    S Sharma
    Department of Pathology, New York Veteran Affairs Medical Center, NY 10010, USA
    Ultrastruct Pathol 22:385-91. 1998
    ..expression of villin (associated with rootlets), cytokeratin 7 (present in lung adenocarcinomas), and cytokeratin 20 (present in colon adenocarcinomas) in 19 formalin-fixed sequential surgical biopsies of lung adenocarcinomas ..
  14. ncbi [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]
    Jia Yu Ling
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 26:418-22. 2007
    ..This study was to analyze the immunophenotypic characteristics of lymphocytic leukemia and NHL with bone marrow involvement using flow cytometry (FCM)...
  15. ncbi High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study
    Thomas M Behr
    Department of Nuclear Medicine, Georg August University of Gottingen, Gottingen, Germany
    Cancer 94:1363-72. 2002
    b>CD20 has been used successfully as a target molecule for conventional low-dose, as well as high-dose, myeloablative radioimmunotherapy (RIT) of B-cell non-Hodgkin lymphoma (NHL)...
  16. ncbi Rapid method for monitoring galactosylation levels during recombinant antibody production by electrospray mass spectrometry with selective-ion monitoring
    H Z Wan
    Department of Manufacturing Sciences, Genentech, Inc, South San Francisco, CA 94080, USA
    J Chromatogr A 913:437-46. 2001
    ..coupled to an HPLC system to quantify the glycoform amounts found on a recombinant antibody that binds to the human CD20 antigen...
  17. doi Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature
    Ofir Wolach
    Internal Medicine A, and Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center Beilinson Hospital, Petah Tikva, Israel
    Medicine (Baltimore) 89:308-18. 2010
    Rituximab is a chimeric monoclonal antibody against CD20 that is used mainly for the treatment of CD20-positive lymphoma...
  18. ncbi Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma
    Shawn K Murray
    Department of Pathology, Capital Health, Halifax, Nova Scotia, Canada
    Am J Surg Pathol 28:1154-62. 2004 detect prostate specific antigen (PSA), prostatic acid phosphatase (PAP), cytokeratin 7 (CK7), cytokeratin 20 (CK20), and carcinoembryonic antigen in LN metastases and in each RA...
  19. ncbi The usefulness of immunohistochemistry in sporadic colorectal cancer
    Camelia Doina Vrabie
    Victor Babes National Institute for Research and Development in Pathology and Biomedical Sciences, Bucharest, Romania
    Rom J Morphol Embryol 49:525-35. 2008
    ..The early detection of colorectal cancer is potential associated with an important decrease of the cancer related mortality...
  20. ncbi Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2
    W G McCluggage
    Department of Pathology, Royal Group of Hospitals Trust, Belfast, Ireland
    Int J Gynecol Pathol 27:92-100. 2008
    ..All cases were stained with cytokeratin (CK) 7, CK20, monoclonal carcinoembryonic antigen (CEA), p16, and CDX2...
  21. ncbi Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Mayo Clinic College of Medicine, Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 40:111-9. 2004
    ..will review the clinical development of ibritumomab tiuxetan, a yttrium-90-conjugated monoclonal antibody to CD20, for patients with relapsed B-cell non-Hodgkin's lymphomas...
  22. ncbi Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy
    H J Haisma
    Departments of Medical Oncology and Otolaryngology Head and Neck Surgery, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Blood 92:184-90. 1998
    The CD20 antigen is an attractive target for specific treatment of B-cell lymphoma...
  23. ncbi Validation of a capillary isoelectric focusing method for the recombinant monoclonal antibody C2B8
    G Hunt
    Department of Quality Control Clinical Development, Genentech Inc, South San Francisco, CA 94080, USA
    J Chromatogr A 800:355-67. 1998
    ..for the purpose of determining the identity and charge distribution of mouse/human chimeric antibody to human CD20 antigen (C2B8)...
  24. ncbi [Combination of thalidomide and rituximab in suppressing myeloma cells in vitro]
    Juan Li
    Department of Hematology, First Affiliated Hospital, Sun Yat Sen University, Guangzhou 510080, P R China
    Ai Zheng 21:1324-7. 2002
    The efficiency of rituximab (Mabthera) is related to CD20 expression density on cell membrane...
  25. ncbi Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens
    D C Chhieng
    Department of Pathology, University of Alabama at Birmingham, 35249 6823, USA
    Cancer 93:330-6. 2001
    ..The combination of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) immunoprofiling has been helpful in the identification of the primary site of origin of lung tumors.
  26. ncbi The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas
    T Tot
    Department of Pathology and Clinical Cytology, Central Hospital, Falun, Sweden
    Cancer 92:2727-32. 2001
    ..Cytokeratin (CK) 5-6 is one of the most specific mesothelioma-associated antibodies. Cytokeratin 20 and CK7 have been used successfully in studies determining primary location of adenocarcinomas from metastases...
  27. ncbi Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7
    Russell Vang
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mod Pathol 19:1421-8. 2006
    ..Immunohistochemical studies were performed to compare expression of CDX2 and cytokeratin 20, both markers of intestinal differentiation, in conjunction with coordinate expression of cytokeratin 7, in 90 ..
  28. ncbi [Value of thyroid transcription factor-1 in identification of the prognosis of bronchioloalveolar carcinoma]
    Chang Li Wang
    Department of Lung Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
    Zhonghua Yi Xue Za Zhi 87:2350-4. 2007
    To study the expression and clinical significance of cytokeratin subtypes CK7 and CK20 and thyroid transcription factor-1 (TTF-1) in bronchioloalveolar carcinoma (BAC), and to investigate the value of these factors in identification of ..
  29. doi An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63
    W Glenn McCluggage
    Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland
    Am J Surg Pathol 34:525-32. 2010
    ..Cases were stained with AE1/3, chromogranin, CD56, synaptophysin, PGP9.5, TTF1, p16, p63, CK7, CK20, neurofilament, and CD99...
  30. ncbi Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms
    P A Bejarano
    Department of Pathology, University of Miami School of Medicine, Florida 33136, USA
    Appl Immunohistochem Mol Morphol 8:189-94. 2000
    ..The combined immunohistochemical profile of TTF-1, TG, cytokeratin 7 (CK7), and cytokeratin 20 (CK20) in neoplasms of the thyroid gland and their metastases to other sites has not been defined previously...
  31. ncbi Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma
    Sanaa Eissa
    Oncology Diagnostic Unit, Biochemistry Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, Egypt
    Clin Biochem 37:803-10. 2004
    We evaluated the diagnostic efficacy of urinary angiogenin (ANG) and cytokeratin 20 (CK-20) mRNA in comparison with voided urine cytology in the detection of bladder cancer patients.
  32. ncbi Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encounter
    Russell Vang
    Department of Pathology and Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Surg Pathol 31:854-69. 2007
    ..origin and exhibit diffuse expression of cytokeratin 7 (CK7) combined with variable expression of cytokeratin 20 (CK20); this immunoprofile distinguishes them from most lower gastrointestinal tract tumors secondarily ..
  33. ncbi [Human/mouse chimeric anti-CD20 monoclonal antibody enhances antigen presentation in dendritic cells and induces anti-lymphoma CTL effects]
    Li Mei Ai
    Department of Hematology, Peking University First Hospital, Beijing 100034, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:1247-52. 2007
    In order to investigate the cellular immunoresponses mediated by chimeric anti-CD20 monoclonal antibody (anti-CD20 McAb) through dendritic cells (DCs), mononuclear cells were isolated from human peripheral blood (PBMNC) and DCs from ..
  34. ncbi Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells
    M Kanzaki
    Department of Cell Biology, Gunma University, Maebashi, Japan
    J Biol Chem 270:13099-104. 1995
    b>CD20 is a transmembrane protein that functions as a Ca(2+)-permeable cation channel (Bubien, J. K., Zhou, L. J., Bell, P. D., Frizzel, R. A., and Tedder, T. F. (1993) J. Cell Biol...
  35. pmc Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum
    Nicole M White
    Biomedical Sciences, Memorial University, St John s, Canada
    Can J Gastroenterol 22:369-75. 2008
    Immunostaining for cytokeratin 7 (CK7) and cytokeratin 20 (CK20) has a characteristic pattern in Barrett's esophagus (BE), but reports regarding its sensitivity and specificity are inconsistent...
  36. ncbi Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting
    R C Braylan
    Department of Pathology, University of Florida, Gainesville, Florida 32610, USA
    Cytometry 46:23-7. 2001
    ..In chronic lymphoproliferative disorders (CLD), 9 antibodies (anti-CD5, CD19, kappa, lambda, CD3, CD20, CD23, CD10, and CD45) were deemed essential for initial evaluation by 75% of the participants...
  37. ncbi Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513 Lodz, Pabianicka 62, Poland
    Leuk Lymphoma 45:937-44. 2004
    ..of this study was to determine the efficacy and toxicity of combined therapy consisting of rituximab (RIT), an anti-CD20 monoclonal antibody, and cladribine (2-chlorodeoxyadenosine, 2-CdA) (RC regimen) in patients with refractory or ..
  38. ncbi Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab
    B Bonnekoh
    Department of Dermatology and Venereology, Otto von Guericke University, Leipziger Strasse 44, 39120 Magdeburg, Germany
    J Cancer Res Clin Oncol 128:161-6. 2002
    Rituximab is a genetically engineered antibody recognizing the CD20 antigen known to be expressed by more than 95% of B-cell lymphomas...
  39. ncbi Immunohistochemical profile of common epithelial neoplasms arising in the kidney
    Mi Kyung Kim
    Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Appl Immunohistochem Mol Morphol 10:332-8. 2002
    ..weight keratin (HCK), and peanut lectin agglutinin (PL) (Arachis hypogaea) were performed on 45 (96 for CK7, CK20) conventional (CC), 20 papillary (PC), and 6 (24 for CK7, CK20) chromophobe renal carcinomas (CPC); 12 oncocytomas (..
  40. ncbi Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
    J Pediatr Hematol Oncol 28:585-93. 2006
    To determine if rituximab, an anti-CD20 monoclonal antibody, reduces cerebrospinal fluid (CSF) B-cell expansion in opsoclonus-myoclonus syndrome (OMS) and results in clinical improvement.
  41. doi CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins
    Maria J Polyak
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    J Biol Chem 283:18545-52. 2008
    ..b>CD20 is a B cell-restricted tetraspanning protein organized in the plasma membrane as multimeric molecular complexes ..
  42. pmc γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
    Mounia Sabrina Braza
    INSERM U1040, Montpellier, France
    Haematologica 96:400-7. 2011
    Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity...
  43. ncbi Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma
    Mateja Horvat
    Bayer d o o, 1000 Ljubljana, Slovenia
    Oncol Rep 24:1101-7. 2010
    The introduction of the anti-CD20 monoclonal antibody, rituximab, into the treatment of patients with B-cell lymphomas has improved the overall response rate, as well as the response duration and the overall survival of these patients...
  44. ncbi Simultaneous effects of lead and cadmium on NK cell activity and some phenotypic parameters
    B Yucesoy
    Department of Toxicology, Faculty of Pharmacy, Ankara University, Tandogan, Turkey
    Immunopharmacol Immunotoxicol 19:339-48. 1997
    ..In the present paper, we investigated the simultaneous effects of lead and cadmium on NK cell activity and CD4+, CD20+ cell percentages in the workers and compared the data with control and lead-exposed groups...
  45. pmc A study of cytokeratin 20 immunostaining in the urothelium of neuropathic bladder of patients with spinal cord injury
    Subramanian Vaidyanathan
    Regional Spinal Injuries Centre, District General Hospital, Southport PR8 6PN, UK
    BMC Urol 2:7. 2002
    Normal urothelium is characterised by terminally differentiated superficial cells, which express cytokeratin 20 in the cytoplasm...
  46. ncbi Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications
    Sanjay Logani
    Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Am J Surg Pathol 27:1434-41. 2003
    ..a panel consisting of antibodies to uroplakin III (UROIII), thrombomodulin (THR), cytokeratin 7 (CK7), cytokeratin 20 (CK20), and Wilms' tumor protein (WT1) to study urothelial differentiation in ovarian transitional cell tumors...
  47. ncbi Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma
    F Bertolini
    Divisions of Hematology Oncology, Experimental Oncology, and Pathology Laboratory Medicine, IRCCS European Institute of Oncology, Milan, Italy
    Blood 96:282-7. 2000
    Both chemotherapy and chimeric anti-CD20 monoclonal antibodies are effective agents against B-cell non-Hodgkin lymphoma (NHL). However, patients achieving remission are at risk of relapse...
  48. pmc Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy
    Yasuhito Hamaguchi
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    J Exp Med 203:743-53. 2006
    b>CD20 monoclonal antibody (mAb) immunotherapy is effective for lymphoma and autoimmune disease...
  49. ncbi Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
    T M Behr
    Department of Nuclear Medicine, Georg August University of Gottingen, Germany
    Clin Cancer Res 5:3304s-3314s. 1999
    Both CD22 and CD20 have been used successfully as target molecules for radioimmunotherapy (RAIT) of low-grade B cell non-Hodgkin's lymphoma...
  50. ncbi Effect of blood sample handling and reverse transcriptase-polymerase chain reaction assay sensitivity on detection of CK20 expression in healthy donor blood
    Femke Vlems
    Department of Surgery, UMC St Radboud, Nijmegen, The Netherlands
    Diagn Mol Pathol 11:90-7. 2002
    Data concerning the specificity of cytokeratin 20 (CK20) as a reverse transcriptase-polymerase chain reaction analysis (RT-PCR) marker to detect disseminated tumor cells in blood are conflicting...
  51. ncbi Flow cytometric evaluation of posttransplant B-cell lymphoproliferative disorders
    Zahid Kaleem
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA
    Arch Pathol Lab Med 128:181-6. 2004
    ..Despite a plethora of information available on the morphologic spectrum, pathogenetic role of Epstein-Barr virus, and various treatment options, a detailed flow cytometric immunophenotypic evaluation of PTLDs is largely lacking...
  52. ncbi Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine
    Guy Ungerechts
    Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota 55902, USA
    Cancer Res 67:10939-47. 2007
    Combination chemotherapy regimen incorporating CD20 antibodies are commonly used in the treatment of CD20-positive non-Hodgkin's lymphoma (NHL)...
  53. ncbi [Detection of cytokeratin20 mRNA in peripheral blood from colonic cancer patients by fluorescence quantitative polymerase chain reaction]
    Zhong cheng Wang
    Department of Clinical Laboratory, Chongqing Emergency Medical Center, Chongqing 400014, China
    Zhonghua Zhong Liu Za Zhi 29:600-3. 2007
    To investigate the expression level of cytokeratin20 mRNA (CK20 mRNA) of cancer cells in peripheral blood from colorectal cancer patients, detected by fluorescence quantitative polymerase chain reaction (FQ-PCR), and to evaluate its ..
  54. ncbi Changes in conjugated linoleic acid and its metabolites in patients with chronic renal failure
    L Lucchi
    Department of Internal Medicine, Division of Nephrology Dialysis and Transplantation, University Hospital of Modena, Modena, Italy
    Kidney Int 58:1695-702. 2000
    ..CLA can be metabolized to conjugated linolenic acid (CD18:3) and to conjugated eicosatrienoic acid (CD20:3) and these metabolites may be implicated in CLA activity...
  55. ncbi Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer
    Robert Rosenberg
    Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstrasse 22, Munich, Germany
    Int J Colorectal Dis 19:430-7. 2004
    ..We therefore evaluated the immunohistochemical detection rates and their prognostic value comparing three different monoclonal antibodies...
  56. doi In vitro evaluation of radioprotective and radiosensitizing effects of rituximab
    Nirav S Kapadia
    School of Medicine, The Johns Hopkins University, Baltimore, MD 21287 0817, USA
    J Nucl Med 49:674-8. 2008
    Clinical radioimmunotherapies with anti-CD20 monoclonal antibodies involve administering a predose of unlabeled anti-CD20 antibodies to favorably alter the biodistribution profile of the subsequently administered radiolabeled antibodies ..
  57. ncbi Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group
    K Tobinai
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo
    Ann Oncol 9:527-34. 1998
    In clinical trials in the USA, IDEC-C2B8 (a mouse-human chimeric anti-CD20 monoclonal antibody) has demonstrated high response rates with only mild toxic effects in relapsed B-cell lymphoma at a dose of four weekly 375 mg/m2 infusions...
  58. ncbi Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response
    J M Foran
    ICRF Medical Oncology Unit, St Bartholomew s Hospital, London, UK
    Ann Oncol 11:117-21. 2000 delineate the factors associated with response, and to determine the duration of response, in 87 patients with CD20-positive mantle-cell lymphoma (MCL) treated with Rituximab (chimeric monoclonal anti-CD20 antibody) in two prior ..
  59. pmc Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection
    K Yamaguchi
    Second Department of Surgery, Gifu University School of Medicine, Gifu, Japan
    Ann Surg 232:58-65. 2000
    To analyze the clinical value of reverse transcriptase-polymerase chain reaction (RT-PCR) recognition of mRNA coding for carcinoembryonic antigen (CEA) and cytokeratin 20 in blood obtained from patients with colorectal carcinoma.
  60. ncbi Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow
    J Thiele
    Institutes of Pathology, University of Cologne, Germany
    Mod Pathol 13:888-96. 2000
    Little information exists about the amount of CD45RO+-T- and CD20+-B-lymphocytes in the bone marrow of patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph1+-CML) at presentation or regarding corresponding ..
  61. doi Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization
    Gordon D Wu
    Comprehensive Transplant Center at Cedars Sinai Medical Center, Los Angeles, CA 90048, United States
    Transpl Immunol 19:178-86. 2008
    B cell depletion by anti-CD20 antibody is used in desensitization protocols and for treatment of antibody-mediated rejection (AMR). However, little is known about the efficacy and the mechanism(s) of action.
  62. doi Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity
    Akito Natsume
    Antibody Research Laboratories, Research Division, Kyowa Hakko Kirin Co, Ltd, Machida shi, Tokyo, Japan
    Cancer Sci 100:2411-8. 2009
    ..factors relating to the host's immune system or tumor cells have been suggested to reduce the efficacy of anti-CD20 therapy in B-cell malignancies...
  63. ncbi Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization
    Mario I Vega
    Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Int J Oncol 35:1289-96. 2009
    Treatment of patients with relapsed or refractory low grade follicular B-NHL lymphoma with rituximab (chimeric anti-CD20 mAb) has resulted in approximately 50% response rate...
  64. ncbi Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study
    Mario Salvi
    Department of Medical Sciences, University of Milan, Fondazione Ospedale Maggiore IRCCS, Milan, Italy
    Eur J Endocrinol 156:33-40. 2007
    ..Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active ..
  65. ncbi Inducible nitric oxide synthase (iNOS) expression in liver and splenic T lymphocyte rise are associated with liver histological damage during experimental hepatitis A virus (HAV) infection in Callithrix jacchus
    M A Pinto
    Department of Virology, IOC FIOCRUZ, Rio de Janeiro, Brazil
    Exp Toxicol Pathol 52:3-10. 2000
    ..No difference was evident in the frequency of B lymphocytes (CD20+)...
  66. ncbi Epstein-Barr virus-positive Hodgkin/Reed-Sternberg-like B cell in non-hodgkin lymphoma: nucleotide sequence of the amplified immunoglobulin heavy-chain variable region gene by the single-cell polymerase chain reaction technique
    Naoya Nakamura
    Department of Pathology, Fukushima Medical University School of Medicine, Fukushima shi, Japan
    Diagn Mol Pathol 11:83-9. 2002
    ..HRS-like B cells were positive for CD20 and CD30 but negative for CD15. EBV presented in HRS-like B cells in both cases but not in any lymphoma cells...
  67. ncbi Rectal carcinoma associated with pagetoid phenomenon
    Ritsuko Haga
    Department of Dermatology, Surugadai Nihon University Hospital, 1 8 13 Kanda Surugadai, Chiyoda ku, Tokyo 101 8309, Japan
    Eur J Dermatol 13:93-4. 2003
    ..The cells were positive for PAS, CEA, and CK20, and negative for GCDFP15 and CK7...
  68. ncbi Detection of parvovirus B19 capsid proteins in lymphocytic cells in synovial tissue of autoimmune chronic arthritis
    Yasmin Mehraein
    Department of Human Genetics, Saarland University, University Hospital, Homburg Saar, Germany
    Mod Pathol 16:811-7. 2003
    ..B19-positive cells in the synovia could be ascribed to CD20- or CD3-positive B- or T-lymphocytes by double immunostaining...
  69. ncbi Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma
    Tsieh Sun
    Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center, Denver, Colorado 80220, USA
    Am J Hematol 74:78-84. 2003
    ..Immunohistochemical stains demonstrated positive staining for CD5 and CD20 and negative staining for CD23 in MCL cases but cyclin D1 was positive in only 10 of 13 MCL cases studied...
  70. ncbi Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases
    Francesco Zaja
    Clinica Ematologica, Policlinico Universitario, P zza S M Misericordia, 33100 Udine, Italy
    Leuk Lymphoma 44:1951-5. 2003
    ..Retreatment of both patients with IT and ADN was effective. Rituximab may be an alternative agent for the treatment CLL-associated autoimmune diseases...
  71. ncbi Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma
    D Vidal
    Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Clin Exp Dermatol 29:518-25. 2004
    ..obtained, the expression of Bcl-2, p53, and Ki-67, apoptotic index (Tunel technique), and the number of CD3+, CD8+, CD20+, CD56+, CD68+, granzyme B+, and S-100+ cells in the peritumoural inflammatory infiltrate, were determined and ..
  72. ncbi CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Robert Marcus
    Dept of Haematology, Addenbrookes Hospital, Cambridge CB2 2QQ, UK
    Blood 105:1417-23. 2005
    ..Rituximab, a chimeric monoclonal antibody against CD20, is active in follicular lymphoma, both as monotherapy and in combination with chemotherapy...
  73. ncbi The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3
    Alja J Stel
    Department of Pathology and Laboratory Medicine, Section Medical Biology Laboratory Tumor Immunology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
    J Immunol 173:6009-16. 2004
    ..BIS20x3 has a dual specificity for both CD20 and CD3 and has previously been shown to effectively direct the lytic potential of cytolytic T cells toward ..
  74. ncbi Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature
    Claire W Michael
    Department of Pathology, University of Michigan, Ann Arbor, Michigan, MI 48109 0054, USA
    Ann Diagn Pathol 9:148-52. 2005
    ..The lymphocytes were positive for CD19, CD20, and CD22...
  75. pmc Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood
    L Moberg
    Department of Oncology, Radiology and Clinical Immunology, Division of Clinical Immunology, Uppsala University Hospital, Sweden
    Clin Exp Immunol 142:125-31. 2005
    ..eosinophilic granulocytes (NaCN + H(2)O(2)), macrophages (CD68), dendritic cells (CD209/DC-SIGN), B cells (CD20) and T cells (CD4, CD8)...
  76. pmc Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer
    Satoshi Ikeda
    Department of Endoscopic Surgery and Surgical Science, Graduate School of Biomedical Science, Hiroshima University, 1 2 3 Kasumi, Hiroshima, Japan
    BMC Cancer 6:31. 2006
    ..The purpose of this study was to evaluate the clinical usefulness of immunohistochemistry of beta-catenin, cytokeratin (CK) 7, and CK20 for the discriminating diagnosis of lung cancer.
  77. ncbi Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors
    W Glenn McCluggage
    Department of Pathology, Royal Group of Hospitals Trust, Belfast, Northern Ireland
    Semin Diagn Pathol 22:3-32. 2005
    ..The well-known CK7 positive, CK20 negative phenotype of primary endometrioid carcinoma, and the converse profile in most metastatic large intestinal ..
  78. ncbi Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach
    Julie Vose
    Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE 681980 7680, USA
    Clin Adv Hematol Oncol 3:923-32. 2005
    ..patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome...
  79. ncbi Radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Thomas E Witzig
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Stabile 6, 200 SW First Street, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 19:655-68. 2006
    ..Both agents target the CD20 antigen on B-cell lymphoma cells...
  80. doi Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity
    Hiroaki Nagashima
    Faculty of Pharmaceutical Sciences, Tokyo University of Science, Yamazaki 2641, Noda, Chiba, Japan
    Mol Immunol 45:2752-63. 2008
    ..A chimeric antibody, designated M-Ab, was constructed with the V regions from mouse anti-CD20 mAb 1F5 and the C regions from human IgG1 and kappa chain...
  81. doi Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein
    Michael O Idowu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:710-8. 2008
    ..2, 34betaE12, CK7, CK20, synaptophysin, chromogranin, and glial fibrillary acidic protein (GFAP) using formalin-fixed, paraffin-embedded ..
  82. doi Rituximab in highly sensitized kidney transplant recipients
    A S Munoz
    Department of Adult Nephrology, National Kidney and Transplant Institute, Quezon City, Philippines
    Transplant Proc 40:2218-21. 2008
    Rituximab, an anti-CD20 monoclonal antibody therapy, depletes B cells and suppresses antibody production. This study sought to describe the efficacy and safety of rituximab among seven highly sensitized kidney transplant patients.
  83. doi Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells
    Amani Mankai
    Immunologie et Pathologie Research Unit, Medical School, Brest, France
    Cancer Res 68:7512-9. 2008
    The anti-CD20 monoclonal antibody rituximab has been less successful in treating chronic lymphocytic leukemia (CLL) than lymphoma, possibly due to the lower density of CD20 on B lymphocytes from CLL patients than on those from lymphoma ..
  84. doi ABO-incompatible adult living donor liver transplantation for hepatocellular carcinoma
    N Matsuno
    5th Department of Surgery, Hachioji Medical Center of Tokyo Medical University, Tokyo, Japan
    Transplant Proc 40:2497-500. 2008
    ..In 5 patients, we administered a single dose of rituximab, a chimeric CD20 monoclonal antibody. As a result of this treatment, 6/8 patients are still alive...
  85. doi Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater
    Daniel Baumhoer
    Institute of Pathology, University of Basel, Schonbeinstrasse 40, 4003 Basel, Switzerland
    Virchows Arch 453:579-88. 2008
    ..We therefore performed immunohistochemistry using a panel of established marker proteins (CK7, CK20, p21, p27, ESA, bax, and ephrin-B2) on 175 carcinoma, 111 adenoma, and 152 normal mucosa specimens of the ampulla ..
  86. doi HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus
    A M Jacobi
    Charite Universitatsmedizin Berlin, Chariteplatz 1, 10098 Berlin, Germany
    Ann Rheum Dis 69:305-8. 2010
    ..subsets in patients with systemic lupus erythematosus (SLE) revealed an activity-related expansion of CD27(++)CD20(-)CD19(dim) Ig-secreting cells...
  87. doi The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells
    Jonna Eeva
    Department of Clinical Microbiology, University of Kuopio, Yliopistoranta 1C, 70210, Kuopio, Finland
    Apoptosis 14:687-98. 2009
    Despite the wide use of anti-CD20 antibody rituximab in the cancer treatment of B cell malignancies, the signalling pathways of CD20-induced apoptosis are still not understood...
  88. ncbi Acute renal failure and bilateral kidney infiltration as the first presentation of non-Hodgkin lymphoma
    Ali Monfared
    Urology Research Center, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
    Iran J Kidney Dis 3:50-3. 2009
    ..Open kidney biopsy was performed and infiltrated cells positive for CD20 and negative for CD3 markers were observed based upon which diagnosis of diffuse large B-cell type non-Hodgkin ..
  89. doi Unusual clinicopathological presentation of primary cutaneous diffuse large B-cell lymphoma, leg type, with multiple nodules and widespread garland-like lesions
    Irena E Belousova
    Department of Dermatology and Venereology, Medical Military Academy, Saint Petersburg, Russia
    Am J Dermatopathol 31:370-4. 2009
    ..lesions and spindle cells identified in the nodule exhibited an identical phenotype: they stained positively for CD20, CD79a, and bcl-2 and tested negative for bcl-6, CD5, CD10, and TdT...
  90. doi A case of small cell carcinoma in the buccal region
    K Nishihara
    Department of Oral and Maxillofacial Surgery, Oral and Maxillofacial Rehabilitation, Kagoshima University Graduate School of Medical and Dental Sciences, 8 35 1 Sakuragaoka, Kagoshima 890 8544, Japan
    Int J Oral Maxillofac Surg 38:1000-3. 2009
    ..tumor cells were positive for cytokeratin (AE1/AE3), neuron-specific enolase (NSE) and CD56, but negative for cytokeratin 20. The patient received chemotherapy and radiotherapy, which resulted in marked regression of the tumor...
  91. doi [Gastric MALT-type lymphoma. Pathology, pathogenesis, diagnostics and therapy]
    M Eck
    Institut fur Pathologie, Klinikum Aschaffenburg, Am Hasenkopf 63704, Aschaffenburg
    Pathologe 31:188-94. 2010
    ..The phenotype of MALT-type lymphoma is identical to non-neoplastic B-lymphocytes of the marginal zone (CD20+, CD5-, CD10- and CD23-). Individual therapy is strongly dependent from histological type and lymphoma stadium...
  92. ncbi Leukemia cutis in B-cell chronic lymphocytic leukemia presenting as an episodic papulovesicular eruption
    Ilana S Rosman
    Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri, USA
    Dermatol Online J 17:7. 2011
    ..Immunohistochemical staining of the lymphocytes showed co-expression of CD20, CD23, CD5, and CD43, consistent with a diagnosis of cutaneous involvement by the patient's CLL...
  93. doi Keratin 20 - a diagnostic and prognostic marker in colorectal cancer?
    Lars Harbaum
    Institute of Pathology, Medical University of Graz, Graz, Austria
    Histol Histopathol 27:347-56. 2012
    Colorectal cancer cells characteristically show strong expression of keratin 20 (K20) and lack expression of keratin 7 (K7). The biological significance of reduced K20 expression, however, is unclear...
  94. doi Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL
    Yuhko Suzuki
    Department of Hematology, Kitasato University School of Medicine, 1 15 1 Kitasato, Minami Ku, Sagamihara, 252 0374, Japan
    Ann Hematol 91:997-1005. 2012
    Diffuse large B-cell lymphomas (DLBCL) express CD20. CD20 expression is described as negative, weak, or normal as determined by flow cytometry (FCM) and is an important target for the treatment of DLBCL...
  95. doi Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature
    Tuelay Kisner
    Renal Division, Department of Medicine and Center for Molecular Medicine, University of Cologne, Cologne, Germany
    Nephron Clin Pract 120:c79-85. 2012
    ..Recently, B cell-directed therapy using the anti-CD20 antibody rituximab has been suggested as induction regimen in pediatric FSGS and MCD patients...
  96. doi Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer
    Zhi Ping Liu
    Department of Oncology, The First Affiliated Hospital of Harbin Medical University, Harbin, PR China
    Onkologie 35:108-13. 2012
    We evaluated the feasibility of CEA/CK20 mRNA and CEA/CA19-9 proteins as tumor markers for colorectal cancer by detecting tumor-specific mRNAs in circulating tumor cells and secreted tumor-specific proteins in the peripheral blood of ..
  97. doi Rituximab maintenance versus retreatment in follicular lymphoma
    Amruth R Palla
    Department of Internal Medicine, Danbury Hospital, Danbury, CT, USA
    Hematol Oncol 31:171-8. 2013
    ..Although the introduction of the anti-CD20 monoclonal antibody rituximab has represented a major breakthrough, FL remains incurable with standard ..
  98. pmc Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells
    Virna Marin
    Centro Ricerca M Tettamanti, Clinica Pediatrica Università Milano Bicocca, Ospedale San Gerardo, 20900 Monza, Italy
    Hum Gene Ther Methods 23:376-86. 2012
    ..thymidine kinase (HSV-TK), human inducible caspase 9 (iCasp9), mutant human thymidylate kinase (mTMPK), and human CD20 codon optimized genes were cloned in frame with 2A-truncated codon optimized CD34 (dCD34) in a retroviral vector...
  99. doi Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience
    Yolanda Braun-Moscovici
    B Shine Rheumatology Unit, Rambam Health Care Campus, PO Box 9602, 31096 Haifa, Israel
    Rheumatol Int 33:1495-504. 2013
    Rituximab (RTX) is a chimeric anti-CD20 antibody, approved for rheumatoid arthritis (RA) patients who failed anti-Tumor Necrosis Factor therapy. It has been used occasionally for life-threatening autoimmune diseases (AID)...
  100. pmc Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates
    Andrea Marzi
    Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA
    Proc Natl Acad Sci U S A 110:1893-8. 2013
    ..Groups of cynomolgus macaques were depleted of CD4+ T, CD8+ T, or CD20+ B cells before and during vaccination with rVSV/ZEBOV-GP...
  101. doi Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia
    Matthew J Barth
    Department of Pediatrics, Roswell Park Cancer Institute, University at Buffalo, Buffalo, NY, USA
    Future Oncol 9:1829-39. 2013
    Ofatumumab is a fully human, IgG anti-CD20 monoclonal antibody codeveloped by GlaxoSmithKline (Brentford, UK) and Genmab (Copenhagen, Denmark)...

Research Grants71

  1. BRENDA MARIE SANDMAIER; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Anti-CD20 monoclonal antibodies (MAb) radiolabeled with b-emitters can achieve remissions in 65-90% of non-Hodgkin lymphoma (NHL) patients failing conventional chemotherapy...
  2. Sherie L Morrison; Fiscal Year: 2015
    ..We have recently succeeded in producing fusion proteins targeting the CD20 antigen expressed on the surface of B cell non-Hodgkin lymphomas...
  3. Targeted therapy of pancreatic cancer with in vivo radionuclide generator
    Ekaterina Dadachova; Fiscal Year: 2012 treat refractory and recurrent lymphomas, with two radiolabeled monoclonal antibodies (mAb) targeted against CD20 (Zevalin(R) and Bexxar(R))...
  4. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2010
    ..Rituximab is a chimeric, murine-human, genetically engineered monoclonal antibody directed against the CD20 antigen found on the surface B-lymphocytes and is known to deplete B cells when administered intravenously...
  5. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2009
    ..Rituximab is a chimeric, murine-human, genetically engineered monoclonal antibody directed against the CD20 antigen found on the surface B-lymphocytes and is known to deplete B cells when administered intravenously...
  6. John M Timmerman; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Anti-CD20 monoclonal antibodies (mAbs) such as rituximab have become a cornerstone in the therapy of B cell non-Hodgkin lymphomas (NHL), but are only partially effective, as most patients eventually ..
  7. Oliver W Press; Fiscal Year: 2015
    ..with B and T cell lymphomas (Aim 1), compare and contrast targeting of lymphoma cells with radiolabeled anti-CD20 and anti-CD45 RAb (Aim 2), compare the relative merits of 111ln-BC8 and 86Y-BC8 for conducting trace-labeled ..
  8. Edward A Neuwelt; Fiscal Year: 2016
    ..after BBBD in newly diagnosed and recurrent PCNSL, and radioimmunotherapy with yttrium-90 labeled anti- CD20 mAb ibritumomab tiuxetan (Zevalin")...
  9. Oliver W Press; Fiscal Year: 2016
    Preliminary clinical trials have demonstrated that radiolabeled anti-CD20 monoclonal antibodies can achieve remissions in 65-90% of lymphoma patients failing chemotherapy...
  10. Identification of biomarkers of fatty acid intake
    Hannia Campos; Fiscal Year: 2002
    ..T lymphocytes (CTL) which have been genetically modified to express a chimeric T cell receptor recognizing the CD20 antigen present on B cell lymphomas...
  11. Martin G Pomper; Fiscal Year: 2014
    ..g., those expressing the B cell surface molecule CD20. Monoclonal antibodies and radioimmunoconjugates such as [131I]Tositumomab (Bexxar") and [90Y]ibritumomab iuxetan (..
  12. Combined radio- and immunotherapy of aggressive NHL
    William A Wegener; Fiscal Year: 2013
    ..NHL Phase I/II clinical trials with 90Y-epratuzumab (humanized anti-CD22 IgG) and veltuzumab (humanized anti-CD20 IgG) have established the maximum tolerated dose (MTD) of a fractionated injection of 90Y-epratuzumab, and the ..
  13. Nanobiotechnology for the Treatment of Mantle Cell Lymphoma
    Trudy Forte; Fiscal Year: 2009
    ..lipid particles, termed nanodisks (ND), protein engineering methods will be employed to target ATRA-ND to the CD20 antigen present on the surface of B lymphocytes...
  14. Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
    Steven H Bernstein; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Rituximab, a chimeric monoclonal antibody directed against CD20, has shown significant therapeutic activity in patients with follicular lymphoma (FL), yet it's exact mechanism of action has not ..
  15. Eric Meffre; Fiscal Year: 2016 well as in humans by successful treatment of rheumatoid arthritis (RA) and other autoimmune diseases with anti-CD20 monoclonal antibodies that eliminate B cells...
  16. Using the Allergic Immune System to Target Cancer
    Joseph Mollick; Fiscal Year: 2009
    ..Monoclonal antibodies to CD20 and two glycosylated forms of MUC1 will be humanized...
  17. Optimizing Therapeutic Index of mAb-IFN_alpha Molecule to Treat Lymphoma
    SANJAY DEEP KHARE; Fiscal Year: 2012
    ..This proposal specifically focuses to optimize anti-CD20-IFN[unreadable] fusion molecule to treat human B cell malignancies...
  18. Brian Till; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Optimization of adoptive immunotherapy with autologous CD20-specific T cells Non-Hodgkin lymphoma is diagnosed in more than 70,000 Americans each year, and aggressive B-cell lymphomas comprise ..
  19. CD20-targeted IL-15 immunotherapeutic for B-cell malignancies
    Hing C Wong; Fiscal Year: 2012
    ..The majority of NHL cases are of B-cell origin and more than 90% express the leukocyte antigen CD20, making these cancers amenable to targeted therapeutic approaches...
  20. Stephen J Forman; Fiscal Year: 2015
    ..In Project 3 investigators will test a molecularly engineered novel anti-CD20 IL-2 immunocytokine for the treatment of patients with 0020"^ lymphoma...
  21. Characterization and Development of a Coiled-Coil to Treat Non-Hodgkin Lymphoma
    Michael Jacobsen; Fiscal Year: 2013
    ..Here, the assembly of coiled- coils was applied to crosslink CD20 receptors on B-cell surfaces, leading to specific induction of apoptosis in these cells...
    Hazel Breitz; Fiscal Year: 2001
    DESCRIPTION (applicant's abstract): The objective of this proposal is to test whether a genetically engineered anti-CD20/streptavidin fusion protein can be used for the initial pretargeting step in the treatment of non-Hodgkin' lymphoma ..
  23. David V Serreze; Fiscal Year: 2016
    ..Results from a recent clinical trial indicated transient depletion of B-lymphocytes with the CD20 specific rituximab antibody did not provide for long-term attenuation of diabetogenic autoimmunity...
  24. miRNA HD Array Platform
    Bruce E Seligmann; Fiscal Year: 2010
    ..biopsies from patients with diffuse large B cell lymphoma (DLBCL), who subsequently received chemotherapy plus anti-CD20 monoclonal Ritixan, will be tested...
  25. B cells in CNS autoimmunity
    Scott S Zamvil; Fiscal Year: 2013
    ..Recent clinical results suggest that anti-CD20 B cell depletion may be effective in MS treatment...
    Yang Shi; Fiscal Year: 2010
    ..Rituximab (chimeric anti-CD20 monoclonal antibody) is the first FDA approved antitumor antibody for the treatment of B-non-Hodgkin's ..
    Maria Lia Palomba; Fiscal Year: 2010
    ..Treatment with anti-CD20 monoclonal antibody, rituximab, is the most successful immune therapy of cancer ever accomplished, and demonstrates ..
  28. Type 1 Diabetes TrialNet at Indiana University Clinical Center
    Linda DiMeglio; Fiscal Year: 2013
    ..One such agent, the anti-CD20 drug rituximab (RituxanR, Genentech, South San Francisco and Biogen) originally developed for treatment of B-cell ..
  29. Molecular Signatures to Improve Diagnosis and Outcome Pr
    Wing Chan; Fiscal Year: 2009
    ..Since existing prognosticators were derived from the study of archival cases prior to the availablility of anti-CD20 therapy, they will be re-evaluated in patients treated with current therapeutic regimens...
  30. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy
    EDMUND ROSSI; Fiscal Year: 2009
    ..The prototype MAb-IFNa, 20-2b, uses the humanized anti-CD20 MAb, veltuzumab, for targeted delivery of IFNa2b for therapy of B-cell lymphoma...
  31. Mechanism of Antibody Therapy in Human B Cell Lymphoma
    Wen Kai Weng; Fiscal Year: 2007
    ..Recently, the successful use of non-toxic monoclonal anti-CD20 antibody, rituximab, to treat B cell lymphoma has produced a great deal of excitement and new hope...
  32. Hyun Soon Chong; Fiscal Year: 2016
    ..containing Y-90 (beta particle-emitting radionuclide), 1B4M-DTPA (bifunctional ligand), and Rituximab (anti-CD20 antibody) significantly enhanced the overall response rate in the treatment of non- Hodgkin's lymphoma (NHL) ..
  33. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy
    Edmund A Rossi; Fiscal Year: 2011
    ..Combination therapy of NHL using IFNa2 and the anti-CD20 monoclonal antibody (MAb) rituximab is more effective than either agent as a monotherapy...
    Timothy Johnson; Fiscal Year: 2003
    ..Preliminary data demonstrate marked synergism in vitro between Iodine-131-radiolabeled anti-CD20 antibody and nucleoside analogs; moderate synergism with topoisomerase inhibitors; and non synergism with cisplatin ..
    Mark Kaminski; Fiscal Year: 2000
    ..We have now demonstrated that radioimmunotherapy (RIT) with 131-I-labeled anti-B1 (anti-CD20) results in major and durable tumor responses in virtually all patients (13 of 13, 10 complete remissions) with ..
    MELISSA CORCORAN; Fiscal Year: 1999
    ..organ ratios of absorbed radiation in a mouse xenograft model utilizing streptavidin-biotin "pretargeted" anti-CD20 antibody and the applicants' current "one step" 131I-anti-CD20 antibody...
  37. MERVYN N WEITZMANN; Fiscal Year: 2016
    ..In Specific Aim 1 we will investigate the impact of B cell depletion in mice in vivo using an anti-CD20 antibody that mimics the agent Rituximab, now used in humans to treat refractory Rheumatoid Arthritis and certain B ..
    Ajay Gopal; Fiscal Year: 2005
    ..of relapsed non-Hodgkin's lymphoma by (1) determining the toxicities and efficacy of myeloablative I-131- anti-CD20 antibody (Ab) combined with cyclophosphamide and etoposide and autologous stem cell transplantation (ASCT) in a ..
    David Maloney; Fiscal Year: 2002
    ..Rituximab, a anti-CD20 mAb induces remissions in 50-60% of patients with follicular NHL...
  40. Yale Autoimmunity Center of Excellence
    Kevan C Herold; Fiscal Year: 2013
    ..The second project is an analysis of autoreactive B cells in T1DM and in patients with T1DM treated with anti-CD20 mAb, in patients with pSS, and in patients with IBD...
    David Wofsy; Fiscal Year: 2013
    ..Two concept proposals are presented. Protocol 1 is a phase Ib/lla trial of anti-CD20 plus cyclophosphamide (IVC) as induction therapy in patients with active lupus nephritis...
  42. Cornelia Bergmann; Fiscal Year: 2016
    ..immune activation due to ectopic B cell follicle formation, as well as improvement in MS patients treated with anti-CD20 monoclonal Ab rituximab to reduce circulating B cells...
  43. Wei Ding; Fiscal Year: 2015
    ..Bendamustine (an alkylating agent) and Rituximab (an antibody targeting CD20) combination therapies have emerged as one of the effective approaches used in the relapsed CLL;however, only ~15% ..
    DAVID WILLIAM SCOTT; Fiscal Year: 2013
    ..We will test the hypothesis that anti-CD20 treatments leads to partial depletion of B cells, sparing the tolerogenic MZ cells...
    Olivia M Martinez; Fiscal Year: 2012
    ..have been utilized to treat patients with PTLD such as anti-viral drugs, B cell specific antibodies including anti-CD20 (Rituximab) and adoptive cellular immunotherapy. However, each of these approaches has distinct limitations...
  46. Optimized Adaptation of Simian-tropic R5 HIV Clade C to Pig-tailed Macaques
    RUTH MARGRIT RUPRECHT; Fiscal Year: 2013
    ..Select stHIV-C progeny with improved replication fitness in PMs under prolonged depletion of CD8+ and CD20+ cells~ 2...
  47. Jennifer Gordon; Fiscal Year: 2014
    ..It is believed that immunosuppression with potent new classes of immunosuppressive agents, including the anti-CD20 molecule, rituximab, allows JC virus to replicate in patients which leads to the development of PML...
  48. Chemoprevention of tobacco carcinogen-induced bladder cancer
    Harikrishna Nakshatri; Fiscal Year: 2011
    ..Increased histone H3 K9 and K27 trimethylation and loss of histone H4 K20 trimethylation are common abnormalities in cancers...
  49. Novel multivalent/multifunctional agents derived from a humanized anti-insulin-li
    Thomas M Cardillo; Fiscal Year: 2010
    ..Past experience with a hexavalent anti-CD20 agent (Hex-hA20) and an anti-CD20-IFN-a2b agent (20-2b) demonstrated superiority in comparison to either the ..
    Roger D Yusen; Fiscal Year: 2011
    ..will use a double blind randomized placebo controlled trial to evaluate the efficacy and safety of IVIG and anti-CD20 antibody...
  51. Novel Cellular Therapies for Ph+ leukemia
    RICHARD A contact VAN ETTEN; Fiscal Year: 2010
    ..NK cells engineered to express activating receptors that recognize ligands on B-lymphoid leukemia cells (CD19 and CD20), and test their efficacy in an in vivo immunotherapy model against human Ph+ B-ALL in NOD/SCID/c mice...
  52. Human B1 Cell Immunoglobulin
    Thomas L Rothstein; Fiscal Year: 2013
    ..This gap has now been filled with our recent finding that human B1 cells co-express CD20, CD27 and CD43, and lack expression of CD70...
    CHAKAR ADRA; Fiscal Year: 2002
    ..hematopoietic cell-specific gene encoding a 4-transmembrane protein homologous to the B cell-specific antigen CD20, and the beta-subunit of the high affinity IgE Fc receptor, FcecRIB...
  54. Alessia Fornoni; Fiscal Year: 2015
    ..FSGS) after transplantation is a highly prevalent condition where rituximab (a monoclonal antibody against CD20) may have a potential indication...
  55. Rituximab for Treatment of Type 1 Diabetes: Impact on JC Viral Proliferation
    MARK DAVID PESCOVITZ; Fiscal Year: 2010
    ..The recently reported, TrialNet-sponsored study using the monoclonal antibody rituximab (anti-CD20) demonstrated that B cells also play a role in the pathogenesis...
  56. JAMES BRUCE BUSSEL; Fiscal Year: 2014
    ..Anti-CD20 (Rituximab, ritux) leads to initial benefit in 50% of ITP patients but3 years after treatment, it appears that only ..
  57. Edward M Schwarz; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): The therapeutic efficacy of TNF antagonists and anti-CD20 B cell depletion therapy in rheumatoid arthritis (RA) have altered pathophysiologic paradigms and generated new questions about underlying ..
  58. Predictive Mathematical Models for Rational Design of Chemoimmunotherapy of Leuke
    Craig A Mullen; Fiscal Year: 2010
    ..kinase inhibitor of the bcr-abl fusion protein);(b) pulsatile methotrexate (an antimetabolite);and (c) anti-CD20 monoclonal antibody...
  59. DANIEL J KASS; Fiscal Year: 2016
    ..double-blind, placebo-controlled Phase II clinical trial to explore the efficacy and safety of rituximab (anti-CD20 monoclonal antibody) vs. placebo, among patients with IPF...
  60. Georges Mer; Fiscal Year: 2016
    ..We will probe several molecular interactions driven by the methylation of histone H4 at lysine 20 (H4-K20) and p53 at lysine 370 (p53-K370), and their possible synergistic coupling to other post-translational ..
  61. Novel Therapies to Improve Renal and Cardiac Allograft Outcomes
    Anil Chandraker; Fiscal Year: 2013 conventional immunosuppression (tacrolimus, MMF and rapid steroid taper) versus induction therapy with anti-CD20 mAb (Rituxan) plus conventional immunosuppression...
  62. KENNETH LYNN WRIGHT; Fiscal Year: 2016
    ..NK cells also kill through antibody- dependent cell-mediated cytotoxicity (ADCC). Rutuximab (anti-CD20) therapy induces NK cell mediated ADCC against some lymphomas including Mantle Cell Lymphoma (MCL)...
  63. Center of Cancer Nanotechnology Excellence Focused on Therapy Response
    Sanjiv S Gambhir; Fiscal Year: 2010
    ..biochemical pathways targeted will be the Her-kinase axis with prostate cancer as the initial focus, and CD20/c-myc with lymphoma as the second initial major focus...
  64. Mechanisms of tolerance in recipients of combined kidney and bone marrow transpla
    Megan Sykes; Fiscal Year: 2010
    ..acute humoral rejection episodes occurred in several patients, resulting in the addition of B cell-depleting anti-CD20 mAb to the regimen...
  65. Natarajan Muthusamy; Fiscal Year: 2016
    ..The introduction of the CD20 antibody rituximab combined with chemotherapy (chemoimmunotherapy) was the first intervention that has been shown ..
  66. Ali Naji; Fiscal Year: 2016
    ..of islet transplantation in Cynomolgus macaques utilizing an induction immunotherapy regimen, which included a CD20 specific B cell depleting agent...
  67. Susheela Tridandapani; Fiscal Year: 2016
    ..One promising form of treatment has been antibody therapy, where CLL cells are targeted by anti-CD20 antibodies such as rituximab and ofatumumab...
  68. John C Cambier; Fiscal Year: 2016
    ..will assess the therapeutic efficacy in T1D of a novel B cell desensitizing therapy, comparing this therapy to anti-CD20, which depletes B cells...
  69. Mechanisms of Regulatory B Cell Function
    Bonnie N Dittel; Fiscal Year: 2013
    ..We found that when B cells were either genetically deficient (?MT) or depleted with anti-CD20 there was a significant reduction in the absolute number of Treg in mice...
  70. Clin.Relevance of Circulat.Tumor Cells in Bladder Cancer
    Iman Osman; Fiscal Year: 2004
    ..The specific aims are: 1) To compare the detection rates of CTC for uroplakins (I-Ill), keratins (k19 and k20), and Epidermal Growth Factor Receptor (EGFR) in patients with superficial bladder cancer versus those with ..
  71. Cytokine Dysregulation in GM-CSF Autoimmunity
    Mary Jane Thomassen; Fiscal Year: 2007
    ..Rituximab, a chimeric murine-human monoclonal antibody directed against the B cell-specific membrane antigen CD20, selectively depletes B cells...